Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020206454 - SYSTEMS AND METHODS FOR RAPID DIAGNOSTIC FOR VARIOUS CANCERS

Publication Number WO/2020/206454
Publication Date 08.10.2020
International Application No. PCT/US2020/026936
International Filing Date 06.04.2020
IPC
G01N 33/574 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
G01N 33/68 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
G16H 10/40 2018.01
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
10ICT specially adapted for the handling or processing of patient-related medical or healthcare data
40for data related to laboratory analysis, e.g. patient specimen analysis
Applicants
  • SAPPHIRE BIOTECH, INC. [US]/[US]
Inventors
  • SVAROVSKY, Sergei
  • SEIT-NEBI, Alim
  • VALENCIA, Catalina
Agents
  • GILLESPIE, Noel C.
  • YVON, Brigitte
Priority Data
62/829,55604.04.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) SYSTEMS AND METHODS FOR RAPID DIAGNOSTIC FOR VARIOUS CANCERS
(FR) SYSTÈMES ET MÉTHODES DE DIAGNOSTIC RAPIDE DE DIVERS CANCERS
Abstract
(EN)
A method for setting a threshold for basal levels of QSOX1-L in urine comprising: Storing de-identified urine from 100 BC patient samples and from 100 patients with non-malignant conditions; serially diluting the patient samples with a blocking buffer in triplicate followed by incubation in ELISA plates coated with anti-QSOX-L capture Ab; after 1-hour incubation at 37C, washing plates followed by addition of biotinylated anti-QSOX-L detection antibody; using Streptavidin-HRP to generate dose dependent signal; obtaining a standard curve for each plate using recombinant QSOX1-L protein spiked into urine that has been depleted of QSOX1-L using affinity chromatography column conjugated with anti-sera against 100aa peptide; calculating concentrations of QSOX1-L based on a standard curve for each plate; and calculating a mean concentrations, ±2 SD to establish a reference range for QSOX1-L levels in urine from patients and individuals without malignant disease.
(FR)
L'invention concerne une méthode de réglage d'un seuil de niveaux de base de QSOX1-L dans l'urine, consistant à : stocker de l'urine anonymisée provenant d'échantillons de 100 patients BC et de 100 patients présentant des états malins ; diluer en série les échantillons de patients avec un tampon de blocage en trois exemplaires, suivi par une incubation dans des plaques ELISA revêtues d'Ab de capture anti-QSOX-L ; après une incubation de 1 heure à 37 °C, laver les plaques puis ajouter un anticorps de détection anti-QSOX-L biotinylé ; utiliser de la streptavidine-HRP pour générer un signal dépendant de la dose ; obtenir une courbe standard pour chaque plaque à l'aide d'une protéine QSOX1-L recombinante étudiée en solution dans l'urine qui a été appauvrie en QSOX1-L au moyen d'une colonne de chromatographie d'affinité conjuguée à des anti-sérums contre un peptide 100aa ; calculer des concentrations de QSOX1-L sur la base d'une courbe standard de chaque plaque ; et calculer des concentrations moyennes, ± 2 SD pour établir une plage de référence de niveaux de QSOX1-L dans l'urine de patients et d'individus ne souffrant pas de maladie maligne.
Latest bibliographic data on file with the International Bureau